MYRIAD GENETICS, INC. Future Amortization Expense, Year Two (Deprecated 2012-01-31)
MYRIAD GENETICS, INC. (MYGN) reported Future Amortization Expense, Year Two (Deprecated 2012-01-31) of $966.00 thousand for the 12-month period ending 2011-06-30, per its 10-K filed 2011-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseYearTwo · last filed 2011-08-15
- MYRIAD GENETICS, INC. future amortization expense, year two (deprecated 2012-01-31) for fiscal 2011 was $966.00K.
| Period end | Future Amortization Expense, Year Two (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-06-30 | $966.00K 10-K · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |